COPD and Diabetes

Living with multiple conditions.

diabetes 2“Which came first–the chicken or the egg?”  Asking the same question regarding chronic obstructive pulmonary disease (COPD) versus diabetes yields a similar conundrum, an ongoing debate in medical research and literature circles. Both COPD and diabetes are serious diseases requiring proper diagnosis and treatment.

COPD and Diabetes Explained

The term COPD encompasses two other lung diseases, chronic bronchitis and emphysema. COPD is progressive and currently incurable, and without proper diagnosis and treatment, health will continue to deteriorate. With COPD, pulmonary inflammation prevents the proper exchange of air. Diabetes or diabetes mellitus is a term used to describe a group of diseases that affect blood sugar, also known as blood glucose, throughout the body. People with diabetes suffer from high amounts of glucose in the blood, which can lead to numerous health complications and adverse symptoms. The hormone insulin regulates glucose levels.

Two top factors cause COPD to develop–smoking and environmental or occupational pollution. For the most part, diabetes occurs because of genetic and environmental factors. The end result for COPD is that the blood is not properly oxygenated, and for diabetes, low levels of insulin result in skyrocketing glucose in the blood which cannot reach the body’s cells to provide energy.

The Connection between COPD and Diabetes

Appearing in Cardiovascular Diabetology, a literature search looked at COPD as a risk factor for diabetes development and vice versa. COPD was viewed as increasing the incidence of diabetes due to its effect on physiological changes like inflammation, resistance to insulin and weight gain. The presence of diabetes was seen to increase the occurrence of lung infections and worsen COPD symptoms causing an increase in flare-ups.

Published in the journal, Thorax, a study looked specifically at the connection between high blood glucose levels with regard to COPD flare-ups. The British group discovered that blood glucose levels were significant in COPD patients who were hospitalized during flare-ups. However, they concluded that more research into the reasons how and why were needed.

A different avenue of research for COPD and diabetes was conducted in Australia. In Diabetes Care, the results of a study of over 18,200 patients showed that there was a corticosteroid dose-dependent risk of hospitalization when an individual had both COPD and diabetes. They concluded that it was important to closely monitor corticosteroid dosage in patients with both diseases.

If you or a loved one has been diagnosed with COPD and want to learn more about treatment options, please contact or call (800) 729-3065 today.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.